A Clinical Trial to Evaluate the Effects of Autologous induced Pluripotent Stem Cell-Derived Natural Killer Cells in Personalized Treatment of Patients with Advanced Metastatic Breast Cancer

General Information

Clinical trials phase Phase 1
Start date (estimated) 2021-02-18
Clinical feature
Label breast cancer
Link http://purl.obolibrary.org/obo/DOID_1612
Description A thoracic cancer that originates in the mammary gland.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200429047241N1
Other study identifiers
Name IRCT20200429047241N1
Description (IRCT registration number)
Source weblink http://en.irct.ir/trial/47603
Regulatory body approval
Name Vice- Chancellor in Research Affairs-Tehran University of Medical Science
Approval number IR.TUMS.VCR.REC.1398.232
Public contact
Email h.khodayari@hotmail.com
Public email h.khodayari@hotmail.com
First name Hamid
Last name Khodayari
Phone +98 21 6658 1587
City Tehran
Address freetext Cancer Institute of Iran, Imam Khomeini Hospital Complex, Tohid Squre, Tehran, Iran
Sponsors International Center for Personalized Medicine (ICPM)


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Not yet recruiting
Estimated number of participants 32